Akeso/Summit's ivonescimab cut death risk 27% vs Merck's Keytruda in HARMONi-2 lung cancer trial; median survival 30.75 vs 22 ...
Welcome back to another edition of Endpoints Weekly! While it is still technically summer, the season is starting to turn now ...
Alzheon, a biotech that has been attempting to treat Alzheimer's with a checkered drug candidate for more than a decade, is ...
Yarrow Bioscience raises $150M; AbbVie's Qulipta succeeds in Phase 3 menstrual migraine trial; Sino Biopharm pays $668M for 5 ...
Andy Plump's upcoming retirement marks another major change to Takeda's leadership team after Christophe Weber handed the keys to Julie Kim.
Oura's S-1 lays out a push beyond wellness into healthcare, with $1.21B in nine-month revenue and FDA device regulation as a ...
Lonza breaks ground on an Oregon spray-drying plant, Samsung Bio lands a $262M deal, and Boston Scientific restores supply post-cyberattack.
Endpoints News reviews 77 E11 startups; highlights include Candid's $2B UCB buyout, Isomorphic Labs' $2.1B raise, Orca Bio's ...
Compass psilocybin drug reports 13-pt reduction in depression score; Solstice debuts with $225M Series A; Luma unveils $410M ...
Anthropic posts a corporate development role for life sciences dealmaking, paying up to $600,000, as its biotech push and IPO ...
Eli Lilly acquires Merida Biosciences for up to $2.875B, gaining MER511 for thyroid eye disease/Graves' disease and MER769 ...
BridgeBio Oncology's stock drops 24% as it narrows BBO-8520 to 2L+ NSCLC, trimming its broader KRAS pipeline plans.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results